{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:29:47Z","timestamp":1787689787754,"version":"build-2784847793"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Key Project of Anhui Provincial Department of Education","award":["2024AH050540"],"award-info":[{"award-number":["2024AH050540"]}]},{"name":"Key Project of Anhui Provincial Department of Education","award":["2025AHGXZK31543"],"award-info":[{"award-number":["2025AHGXZK31543"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s12265-026-10794-4","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:01:18Z","timestamp":1780938078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Mechanisms and Clinical Applications of SGLT2 Inhibitors in Cardiovascular Diseases"],"prefix":"10.1007","volume":"19","author":[{"given":"Cong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pangbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8767-0934","authenticated-orcid":false,"given":"Simin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"9","key":"10794_CR1","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/ejhf.3347","volume":"26","author":"PM Seferovi\u0107","year":"2024","unstructured":"Seferovi\u0107 PM, Paulus WJ, Rosano G, et al. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. Eur J Heart Fail. 2024;26(9):1893\u2013903. https:\/\/doi.org\/10.1002\/ejhf.3347.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10794_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"JR Ehrenkranz","year":"2005","unstructured":"Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31\u20138. https:\/\/doi.org\/10.1002\/dmrr.532.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10794_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"EM Wright","year":"2007","unstructured":"Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32\u201343. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01746.x.","journal-title":"J Intern Med"},{"issue":"2","key":"10794_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1172\/jci102424","volume":"30","author":"SJ Farber","year":"1951","unstructured":"Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30(2):125\u20139. https:\/\/doi.org\/10.1172\/jci102424.","journal-title":"J Clin Invest"},{"key":"10794_CR5","doi-asserted-by":"publisher","unstructured":"Choi CI. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents. Molecules. 2016;21(9). https:\/\/doi.org\/10.3390\/molecules21091136.","DOI":"10.3390\/molecules21091136"},{"key":"10794_CR6","doi-asserted-by":"publisher","first-page":"175394472110026","DOI":"10.1177\/17539447211002678","volume":"15","author":"MV Genuardi","year":"2021","unstructured":"Genuardi MV, Mather PJ. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Ther Adv Cardiovasc Dis. 2021;15:17539447211002678. https:\/\/doi.org\/10.1177\/17539447211002678.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"8","key":"10794_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2174\/0929867323666160210125747","volume":"23","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu ZP. Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors. Curr Med Chem. 2016;23(8):832\u201349. https:\/\/doi.org\/10.2174\/0929867323666160210125747.","journal-title":"Curr Med Chem"},{"issue":"12","key":"10794_CR8","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.34067\/kid.0002772021","volume":"2","author":"EM Wright","year":"2021","unstructured":"Wright EM. SGLT2 Inhibitors: Physiology and Pharmacology. Kidney 360. 2021;2(12):2027\u201337. https:\/\/doi.org\/10.34067\/kid.0002772021.","journal-title":"Kidney 360"},{"key":"10794_CR9","doi-asserted-by":"publisher","unstructured":"Azizogli AR, Vitti MR, Mishra R, et al. Comparison of SGLT1, SGLT2, and Dual Inhibitor biological activity in treating Type 2 Diabetes Mellitus. Adv Ther (Weinh). 2023;6(12). https:\/\/doi.org\/10.1002\/adtp.202300143.","DOI":"10.1002\/adtp.202300143"},{"issue":"7892","key":"10794_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41586-021-04212-9","volume":"601","author":"Y Niu","year":"2022","unstructured":"Niu Y, Liu R, Guan C, et al. Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter. Nature. 2022;601(7892):280\u20134. https:\/\/doi.org\/10.1038\/s41586-021-04212-9.","journal-title":"Nature"},{"issue":"10","key":"10794_CR11","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"C Ghezzi","year":"2018","unstructured":"Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087\u201397. https:\/\/doi.org\/10.1007\/s00125-018-4656-5.","journal-title":"Diabetologia"},{"issue":"1","key":"10794_CR12","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1038\/s41467-018-07700-1","volume":"9","author":"P Bisignano","year":"2018","unstructured":"Bisignano P, Ghezzi C, Jo H, et al. Inhibitor binding mode and allosteric regulation of Na(+)-glucose symporters. Nat Commun. 2018;9(1):5245. https:\/\/doi.org\/10.1038\/s41467-018-07700-1.","journal-title":"Nat Commun"},{"issue":"3","key":"10794_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jacasi.2022.03.009","volume":"2","author":"Y Kubota","year":"2022","unstructured":"Kubota Y, Shimizu W. Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC Asia. 2022;2(3):287\u201393. https:\/\/doi.org\/10.1016\/j.jacasi.2022.03.009.","journal-title":"JACC Asia"},{"issue":"10","key":"10794_CR14","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","volume":"36","author":"W Liu","year":"2024","unstructured":"Liu W, You D, Lin J, et al. SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8(+) T cell activation. Cell Metab. 2024;36(10):2245\u201361. https:\/\/doi.org\/10.1016\/j.cmet.2024.08.005.","journal-title":"Cell Metab"},{"issue":"3","key":"10794_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213\u201325. https:\/\/doi.org\/10.1007\/s40262-013-0126-x.","journal-title":"Clin Pharmacokinet"},{"issue":"47","key":"10794_CR16","doi-asserted-by":"publisher","first-page":"9480","DOI":"10.1021\/bi301329w","volume":"51","author":"X Jiang","year":"2012","unstructured":"Jiang X, Loo DD, Hirayama BA, Wright EM. The importance of being aromatic: \u03c0 interactions in sodium symporters. Biochemistry. 2012;51(47):9480. https:\/\/doi.org\/10.1021\/bi301329w.","journal-title":"Biochemistry"},{"issue":"1","key":"10794_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K, et al. Interaction of the Sodium\/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther. 2016;358(1):94\u2013102. https:\/\/doi.org\/10.1124\/jpet.116.232025.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10794_CR18","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1080\/15548627.2021.1969633","volume":"18","author":"TD Heden","year":"2022","unstructured":"Heden TD, Chow LS, Hughey CC, Mashek DG. Regulation and role of glycophagy in skeletal muscle energy metabolism. Autophagy. 2022;18(5):1078\u201389. https:\/\/doi.org\/10.1080\/15548627.2021.1969633.","journal-title":"Autophagy"},{"key":"10794_CR19","doi-asserted-by":"publisher","first-page":"817542","DOI":"10.3389\/fphys.2022.817542","volume":"13","author":"X Yu","year":"2022","unstructured":"Yu X, Meng Z, Fang T, et al. Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK\/CREB\/GSK3\u03b2 Signalling Pathway. Front Physiol. 2022;13:817542. https:\/\/doi.org\/10.3389\/fphys.2022.817542.","journal-title":"Front Physiol"},{"issue":"22","key":"10794_CR20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"10794_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/b978-0-12-394316-3.00002-8","volume":"70","author":"M Raja","year":"2012","unstructured":"Raja M, Puntheeranurak T, Hinterdorfer P, Kinne R. SLC5 and SLC2 transporters in epithelia-cellular role and molecular mechanisms. Curr Top Membr. 2012;70:29\u201376. https:\/\/doi.org\/10.1016\/b978-0-12-394316-3.00002-8.","journal-title":"Curr Top Membr"},{"issue":"1","key":"10794_CR22","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41598-024-52331-w","volume":"14","author":"AA Sayour","year":"2024","unstructured":"Sayour AA, Ol\u00e1h A, Ruppert M, et al. Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis. Sci Rep. 2024;14(1):2188. https:\/\/doi.org\/10.1038\/s41598-024-52331-w.","journal-title":"Sci Rep"},{"issue":"5","key":"10794_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","volume":"13","author":"K Jiang","year":"2022","unstructured":"Jiang K, Xu Y, Wang D, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022;13(5):336\u201359. https:\/\/doi.org\/10.1007\/s13238-020-00809-4.","journal-title":"Protein Cell"},{"issue":"8","key":"10794_CR24","doi-asserted-by":"publisher","first-page":"e16868","DOI":"10.7759\/cureus.16868","volume":"13","author":"N Srinivas","year":"2021","unstructured":"Srinivas N, Sarnaik MK, Modi S, et al. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus. Cureus. 2021;13(8):e16868. https:\/\/doi.org\/10.7759\/cureus.16868.","journal-title":"Cureus"},{"issue":"5","key":"10794_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, Montecucco F, Carbone F, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120(5):443\u201360. https:\/\/doi.org\/10.1093\/cvr\/cvae047.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10794_CR26","doi-asserted-by":"publisher","first-page":"834","DOI":"10.2146\/news130035","volume":"70","author":"K Traynor","year":"2013","unstructured":"Traynor K. Canagliflozin approved for type 2 diabetes. Am J Health Syst Pharm. 2013;70(10):834. https:\/\/doi.org\/10.2146\/news130035.","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"10794_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"4","key":"10794_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"4","key":"10794_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4093\/dmj.2014.38.4.261","volume":"38","author":"CH Jung","year":"2014","unstructured":"Jung CH, Jang JE, Park JY. A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes Metab J. 2014;38(4):261\u201373. https:\/\/doi.org\/10.4093\/dmj.2014.38.4.261.","journal-title":"Diabetes Metab J"},{"issue":"21","key":"10794_CR30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"12","key":"10794_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"15","key":"10794_CR32","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"15","key":"10794_CR33","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"16","key":"10794_CR34","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"3","key":"10794_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"issue":"11","key":"10794_CR36","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/circulationaha.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation. 2020;142(11):1028\u201339. https:\/\/doi.org\/10.1161\/circulationaha.120.045691.","journal-title":"Circulation"},{"issue":"6","key":"10794_CR37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/dom.13251","volume":"20","author":"R Aronson","year":"2018","unstructured":"Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20(6):1453\u201360. https:\/\/doi.org\/10.1111\/dom.13251.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10794_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/dom.13116","volume":"20","author":"S Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530\u201340. https:\/\/doi.org\/10.1111\/dom.13116.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10794_CR39","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2004967.","journal-title":"N Engl J Med"},{"issue":"9","key":"10794_CR40","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40265-019-01146-5","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ, Sotagliflozin. First Global Approval. Drugs. 2019;79(9):1023\u20139. https:\/\/doi.org\/10.1007\/s40265-019-01146-5.","journal-title":"Drugs"},{"issue":"2","key":"10794_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2030186.","journal-title":"N Engl J Med"},{"issue":"8 Pt 1","key":"10794_CR42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","volume":"11","author":"B Pitt","year":"2023","unstructured":"Pitt B, Bhatt DL, Szarek M, et al. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF. JACC Heart Fail. 2023;11(8 Pt 1):879\u201389. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.026.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10794_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2030183.","journal-title":"N Engl J Med"},{"issue":"8","key":"10794_CR44","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40265-014-0229-1","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs. 2014;74(8):939\u201344. https:\/\/doi.org\/10.1007\/s40265-014-0229-1.","journal-title":"Drugs"},{"key":"10794_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1475-2840-13-65","volume":"13","author":"K Kaku","year":"2014","unstructured":"Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65. https:\/\/doi.org\/10.1186\/1475-2840-13-65.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10794_CR46","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/jdi.14287","volume":"15","author":"Y Yamada","year":"2024","unstructured":"Yamada Y, Yabe D, Shide K, et al. Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice. J Diabetes Investig. 2024;15(11):1585\u201395. https:\/\/doi.org\/10.1111\/jdi.14287.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10794_CR47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-020-01079-4","volume":"19","author":"N Katakami","year":"2020","unstructured":"Katakami N, Mita T, Yoshii H, et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;19(1):110. https:\/\/doi.org\/10.1186\/s12933-020-01079-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10794_CR48","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-023-01848-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM, Bexagliflozin. First Approval Drugs. 2023;83(5):447\u201353. https:\/\/doi.org\/10.1007\/s40265-023-01848-x.","journal-title":"First Approval Drugs"},{"issue":"24","key":"10794_CR49","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"2","key":"10794_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"4","key":"10794_CR51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/circulationaha.120.051685","volume":"143","author":"F Zannad","year":"2021","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Circulation. 2021;143(4):310\u201321. https:\/\/doi.org\/10.1161\/circulationaha.120.051685.","journal-title":"Circulation"},{"issue":"12","key":"10794_CR52","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jacc.2024.06.036","volume":"84","author":"AS Bhatt","year":"2024","unstructured":"Bhatt AS, Bhatt DL, Steg PG, et al. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF. J Am Coll Cardiol. 2024;84(12):1078\u201388. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.036.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10794_CR53","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"41","key":"10794_CR54","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","volume":"43","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehac494.","journal-title":"Eur Heart J"},{"issue":"14","key":"10794_CR55","doi-asserted-by":"publisher","first-page":"e027824","DOI":"10.1161\/jaha.122.027824","volume":"12","author":"O Kwon","year":"2023","unstructured":"Kwon O, Myong JP, Lee Y, et al. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation. J Am Heart Assoc. 2023;12(14):e027824. https:\/\/doi.org\/10.1161\/jaha.122.027824.","journal-title":"J Am Heart Assoc"},{"key":"10794_CR56","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ahj.2023.08.008","volume":"266","author":"S James","year":"2023","unstructured":"James S, Erlinge D, Storey RF, et al. Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. Am Heart J. 2023;266:188\u201397. https:\/\/doi.org\/10.1016\/j.ahj.2023.08.008.","journal-title":"Am Heart J"},{"issue":"16","key":"10794_CR57","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2314051.","journal-title":"N Engl J Med"},{"issue":"3","key":"10794_CR58","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320. https:\/\/doi.org\/10.1016\/s2213-8587(15)00417-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10794_CR59","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u20138. https:\/\/doi.org\/10.2337\/dc14-1096.","journal-title":"Diabetes Care"},{"issue":"21","key":"10794_CR60","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099. https:\/\/doi.org\/10.1056\/NEJMc1712572.","journal-title":"N Engl J Med"},{"issue":"12","key":"10794_CR61","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s2213-8587(20)30344-2","volume":"8","author":"DK McGuire","year":"2020","unstructured":"McGuire DK, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol. 2020;8(12):949\u201359. https:\/\/doi.org\/10.1016\/s2213-8587(20)30344-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 5","key":"10794_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.15751","volume":"26","author":"AX Chen","year":"2024","unstructured":"Chen AX, Fletcher R, Neuen BL, Neal B, Arnott C. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes Obes Metab. 2024;26(Suppl 5):5\u201313. https:\/\/doi.org\/10.1111\/dom.15751.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10794_CR63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ehjcvp\/pvae022","volume":"10","author":"TE Eroglu","year":"2024","unstructured":"Eroglu TE, Coronel R, Souverein PC. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. Eur Heart J Cardiovasc Pharmacother. 2024;10(4):289\u201395. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae022.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"15","key":"10794_CR64","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/circulationaha.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227\u201334. https:\/\/doi.org\/10.1161\/circulationaha.119.044183.","journal-title":"Circulation"},{"issue":"1","key":"10794_CR65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","volume":"20","author":"HL Li","year":"2021","unstructured":"Li HL, Lip GYH, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):100. https:\/\/doi.org\/10.1186\/s12933-021-01293-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10794_CR66","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372. https:\/\/doi.org\/10.1038\/s41569-020-0406-8.","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10794_CR67","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.5551\/jat.52100","volume":"27","author":"A Rahadian","year":"2020","unstructured":"Rahadian A, Fukuda D, Salim HM, et al. Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice. J Atheroscler Thromb. 2020;27(11):1141\u201351. https:\/\/doi.org\/10.5551\/jat.52100.","journal-title":"J Atheroscler Thromb"},{"key":"10794_CR68","doi-asserted-by":"publisher","unstructured":"Mal\u00ednsk\u00e1 H, H\u00fcttl M, Markov\u00e1 I, et al. Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein. Biomedicines. 2022;10(9). https:\/\/doi.org\/10.3390\/biomedicines10092066.","DOI":"10.3390\/biomedicines10092066"},{"issue":"2","key":"10794_CR69","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000531084","volume":"55","author":"M Packer","year":"2024","unstructured":"Packer M. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia. Am J Nephrol. 2024;55(2):255\u20139. https:\/\/doi.org\/10.1159\/000531084.","journal-title":"Am J Nephrol"},{"key":"10794_CR70","doi-asserted-by":"publisher","first-page":"122486","DOI":"10.1016\/j.lfs.2024.122486","volume":"341","author":"Q Huo","year":"2024","unstructured":"Huo Q, Yue T, Li W, et al. Empagliflozin attenuates radiation-induced hematopoietic damage via NOX-4\/ROS\/p38 pathway. Life Sci. 2024;341:122486. https:\/\/doi.org\/10.1016\/j.lfs.2024.122486.","journal-title":"Life Sci"},{"key":"10794_CR71","doi-asserted-by":"publisher","unstructured":"Actis Dato V, Lange S, Cho Y. Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases. Int J Mol Sci. 2024;25(2). https:\/\/doi.org\/10.3390\/ijms25021211.","DOI":"10.3390\/ijms25021211"},{"issue":"9","key":"10794_CR72","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4239\/wjd.v13.i9.683","volume":"13","author":"V Quentin","year":"2022","unstructured":"Quentin V, Singh M, Nguyen LS. A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena. World J Diabetes. 2022;13(9):683\u201395. https:\/\/doi.org\/10.4239\/wjd.v13.i9.683.","journal-title":"World J Diabetes"},{"issue":"6","key":"10794_CR73","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1097\/xcs.0000000000001021","volume":"238","author":"DD Harris","year":"2024","unstructured":"Harris DD, Sabe SA, Broadwin M, et al. Proteomic Analysis and Sex-Specific Changes in Chronically Ischemic Swine Myocardium Treated with Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin. J Am Coll Surg. 2024;238(6):1045\u201355. https:\/\/doi.org\/10.1097\/xcs.0000000000001021.","journal-title":"J Am Coll Surg"},{"key":"10794_CR74","doi-asserted-by":"publisher","first-page":"1291450","DOI":"10.3389\/fcvm.2023.1291450","volume":"10","author":"S Su","year":"2023","unstructured":"Su S, Ji X, Li T, et al. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy. Front Cardiovasc Med. 2023;10:1291450. https:\/\/doi.org\/10.3389\/fcvm.2023.1291450.","journal-title":"Front Cardiovasc Med"},{"key":"10794_CR75","doi-asserted-by":"publisher","unstructured":"Katsurada K. Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states. Hypertens Res 2025https:\/\/doi.org\/10.1038\/s41440-025-02216-w","DOI":"10.1038\/s41440-025-02216-w"},{"issue":"6","key":"10794_CR76","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s42255-024-01036-5","volume":"6","author":"H Wang","year":"2024","unstructured":"Wang H, Wang J, Cui H, et al. Inhibition of fatty acid uptake by TGR5 prevents diabetic cardiomyopathy. Nat Metab. 2024;6(6):1161\u201377. https:\/\/doi.org\/10.1038\/s42255-024-01036-5.","journal-title":"Nat Metab"},{"key":"10794_CR77","doi-asserted-by":"publisher","unstructured":"Mylonas N, Nikolaou PE, Karakasis P, et al. Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies. Int J Mol Sci. 2024;25(13). https:\/\/doi.org\/10.3390\/ijms25137274.","DOI":"10.3390\/ijms25137274"},{"issue":"9","key":"10794_CR78","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/13543784.2023.2263354","volume":"32","author":"I Forzano","year":"2023","unstructured":"Forzano I, Wilson S, Lombardi A, et al. SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opin Investig Drugs. 2023;32(9):839\u201347. https:\/\/doi.org\/10.1080\/13543784.2023.2263354.","journal-title":"Expert Opin Investig Drugs"},{"key":"10794_CR79","doi-asserted-by":"publisher","unstructured":"Ala M. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. Endocrinology. 2021;162(12). https:\/\/doi.org\/10.1210\/endocr\/bqab157.","DOI":"10.1210\/endocr\/bqab157"},{"issue":"5","key":"10794_CR80","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","volume":"313","author":"L Tang","year":"2017","unstructured":"Tang L, Wu Y, Tian M, et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313(5):E563\u201376. https:\/\/doi.org\/10.1152\/ajpendo.00086.2017.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10794_CR81","doi-asserted-by":"publisher","first-page":"174715","DOI":"10.1016\/j.ejphar.2021.174715","volume":"918","author":"E Abdollahi","year":"2022","unstructured":"Abdollahi E, Keyhanfar F, Delbandi AA, et al. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages. Eur J Pharmacol. 2022;918:174715. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174715.","journal-title":"Eur J Pharmacol"},{"issue":"19","key":"10794_CR82","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1161\/circulationaha.122.062984","volume":"150","author":"C Panico","year":"2024","unstructured":"Panico C, Felicetta A, Kunderfranco P, et al. Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction. Circulation. 2024;150(19):1517\u201332. https:\/\/doi.org\/10.1161\/circulationaha.122.062984.","journal-title":"Circulation"},{"issue":"6","key":"10794_CR83","doi-asserted-by":"publisher","first-page":"e011107","DOI":"10.1161\/circheartfailure.123.011107","volume":"17","author":"A Schauer","year":"2024","unstructured":"Schauer A, Adams V, K\u00e4mmerer S, et al. Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain. Circ Heart Fail. 2024;17(6):e011107. https:\/\/doi.org\/10.1161\/circheartfailure.123.011107.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10794_CR84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. https:\/\/doi.org\/10.1186\/s12933-019-0816-2.","journal-title":"Cardiovasc Diabetol"},{"key":"10794_CR85","doi-asserted-by":"publisher","first-page":"873108","DOI":"10.3389\/fphar.2022.873108","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Yang Q, Bai W, et al. Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-\u03b21\/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure. Front Pharmacol. 2022;13:873108. https:\/\/doi.org\/10.3389\/fphar.2022.873108.","journal-title":"Front Pharmacol"},{"issue":"2","key":"10794_CR86","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jphs.2017.10.006","volume":"137","author":"L Li","year":"2018","unstructured":"Li L, Konishi Y, Morikawa T, et al. Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats. J Pharmacol Sci. 2018;137(2):220\u20133. https:\/\/doi.org\/10.1016\/j.jphs.2017.10.006.","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"10794_CR87","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","volume":"21","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Curr Cardiol Rep. 2019;21(8):70. https:\/\/doi.org\/10.1007\/s11886-019-1165-1.","journal-title":"Curr Cardiol Rep"},{"issue":"15","key":"10794_CR88","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10794_CR89","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41440-020-0410-8","volume":"43","author":"N Wan","year":"2020","unstructured":"Wan N, Fujisawa Y, Kobara H, et al. Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. Hypertens Res. 2020;43(6):492\u20139. https:\/\/doi.org\/10.1038\/s41440-020-0410-8.","journal-title":"Hypertens Res"},{"key":"10794_CR90","doi-asserted-by":"publisher","unstructured":"Karpushev AV, Mikhailova VB, Klimenko ES, et al. SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart. Int J Mol Sci. 2022;23(17). https:\/\/doi.org\/10.3390\/ijms23179559.","DOI":"10.3390\/ijms23179559"},{"issue":"1","key":"10794_CR91","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"C Lahnwong","year":"2020","unstructured":"Lahnwong C, Palee S, Apaijai N, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovasc Diabetol. 2020;19(1):91. https:\/\/doi.org\/10.1186\/s12933-020-01066-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10794_CR92","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1083\/jcb.149.7.1503","volume":"149","author":"PD Lampe","year":"2000","unstructured":"Lampe PD, TenBroek EM, Burt JM, et al. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. J Cell Biol. 2000;149(7):1503\u201312. https:\/\/doi.org\/10.1083\/jcb.149.7.1503.","journal-title":"J Cell Biol"},{"issue":"2","key":"10794_CR93","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1161\/circresaha.117.310230","volume":"121","author":"DA Eisner","year":"2017","unstructured":"Eisner DA, Caldwell JL, Kistam\u00e1s K, Trafford AW. Calcium and Excitation-Contraction Coupling in the Heart. Circ Res. 2017;121(2):181\u201395. https:\/\/doi.org\/10.1161\/circresaha.117.310230.","journal-title":"Circ Res"},{"issue":"3","key":"10794_CR94","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, et al. Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. Cardiovasc Drugs Ther. 2017;31(3):233\u201346. https:\/\/doi.org\/10.1007\/s10557-017-6734-1.","journal-title":"Cardiovasc Drugs Ther"},{"key":"10794_CR95","doi-asserted-by":"publisher","unstructured":"Mourad O, Vohra S, Nunes SS. Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure. 2025;15:8265. https:\/\/doi.org\/10.1038\/s41598-025-93144-9","DOI":"10.1038\/s41598-025-93144-9"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10794-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10794-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10794-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:01:20Z","timestamp":1780938080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10794-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10794"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10794-4","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests:","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}